Ownership history in Crestline Management, LP · 33 quarters on record
This page tracks every 13F SEC filing in which Crestline Management, LP reported a position in DENALI THERAPEUTICS INC (DNLI). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 2,810,732 | -600,000 | -17.6% | 87.02% | $46.4M | $16.51 |
| 2025 Q3 | REDUCED | 3,410,732 | -450,000 | -11.7% | 85.26% | $49.52B | $14.52 |
| 2025 Q2 | REDUCED | 3,860,732 | -300,000 | -7.2% | 86.33% | $54.01B | $13.99 |
| 2025 Q1 | REDUCED | 4,160,732 | -150,000 | -3.5% | 89.45% | $56.57B | $13.60 |
| 2024 Q4 | REDUCED | 4,310,732 | -150,000 | -3.4% | 2.92% | $87.9M | $20.38 |
| 2024 Q3 | REDUCED | 4,460,732 | -300,000 | -6.3% | 6.75% | $129.9M | $29.13 |
| 2024 Q2 | REDUCED | 4,760,732 | -450,000 | -8.6% | 8.60% | $110.5M | $23.22 |
| 2024 Q1 | REDUCED | 5,210,732 | -450,000 | -7.9% | 9.45% | $106.9M | $20.52 |
| 2023 Q4 | REDUCED | 5,660,732 | -300,000 | -5.0% | 10.35% | $121.5M | $21.46 |
| 2023 Q3 | REDUCED | 5,960,732 | -150,000 | -2.5% | 14.32% | $123.0M | $20.63 |
As of 2025 Q4 — sorted by position size